Litigation Details for Abu Dhabi Investment Authority v. Mylan N.V. (S.D.N.Y. 2020)
✉ Email this page to a colleague
Abu Dhabi Investment Authority v. Mylan N.V. (S.D.N.Y. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-02-14 |
| Court | District Court, S.D. New York | Date Terminated | |
| Cause | 15:78m(a) Securities Exchange Act | Assigned To | James Paul Oetken |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 7,449,012; 7,794,432; 8,048,035; 8,870,827 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Abu Dhabi Investment Authority v. Mylan N.V.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Abu Dhabi Investment Authority v. Mylan N.V. (S.D.N.Y. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-02-14 | 1 | Complaint | expiration of U.S. Patent Nos. 7,449,012 B2 (the “012 patent’) and 7,794,432 B2 (the “432 patent’), which expire…additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent Nos. 7,449,012…8,048,035, and 8,870,827 (the “EpiPen Patents”). These four patents have a priority date (i.e., the date…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as covering the EpiPen, further…submitted information concerning the ‘012 patent and ‘432 patent for listing in the FDA’s [Orange Book] | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
